On the Record · Bioverativ
Bioverativ competitors, on the record
The companies Bioverativ names as competitors in its annual reports, 2016 to 2017, and the companies that name Bioverativ, each with the sentence and the filing.
Who Bioverativ names
| Company | Named in |
|---|---|
| Alnylam Pharmaceuticals | 2017 |
| Bayer AG | 2017 |
| CSL Ltd. | 2017 |
| Novo Nordisk | 2017 |
| Pfizer Inc. | 2017 |
| Roche Holding AG | 2017 |
| Sanofi Genzyme | 2017 |
| Shire Plc. | 2017 |
In its own words
Alnylam Pharmaceuticals, Bayer AG, CSL Ltd., Novo Nordisk, Pfizer Inc., Roche Holding AG, Sanofi Genzyme, Shire Plc.
Word for word“A number of companies, including some mid-to-large biopharmaceutical companies, such as Alnylam Pharmaceuticals, Bayer AG, Novo Nordisk, CSL Ltd., Pfizer Inc., Roche Holding AG, Sanofi Genzyme and Shire Plc., currently market or are pursuing the development of products for the treatment of hemophilia.” 10-K for 2017
Who names Bioverativ
Companies whose own annual reports name Bioverativ as a competitor.
Word for word“The principal sources of competition for ADVATE and ADYNOVATE globally are: XYNTHA/REFACTO AF (Pfizer and SOBI); KOGENATE (Bayer); HELIXATE (CSL); KOVALTRY (Bayer); Iblias (CSL); ELOCTATE/ELOCTA (Bioverativ and SOBI); NOVOEIGHT (Novo Nordisk); and NUWIQ (Octapharma); Afstyla (CSL).” 10-K for 2017
Read from Bioverativ’s annual reports (10-K for 2017, 10-K for 2016) and the financial data it files with the SEC, as of 2018-02-14. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.